Compare IMRX & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMRX | ACIU |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.7M | 288.0M |
| IPO Year | 2021 | 2015 |
| Metric | IMRX | ACIU |
|---|---|---|
| Price | $5.37 | $2.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $17.20 | $10.00 |
| AVG Volume (30 Days) | ★ 737.9K | 250.4K |
| Earning Date | 05-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $706.75 |
| Revenue Next Year | N/A | $321.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.40 | $1.60 |
| 52 Week High | $10.08 | $4.00 |
| Indicator | IMRX | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 43.74 |
| Support Level | $5.31 | $2.80 |
| Resistance Level | $5.80 | $3.13 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 28.99 | 32.00 |
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.